Recombinant Human Anti-MCP1 Antibody (cnto888) (CAT#: PABX-141)

Anti-MCP1 antibody is a Human antibody of IgG class that binds to an MCP1. It developed From human combinatorial antibody library.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Immunoblot analysis of Akt, p70S6 kinase, and mitogen-activated protein kinase p44/p42 activation.

Figure 1 Immunoblot analysis of Akt, p70S6 kinase, and mitogen-activated protein kinase p44/p42 activation.

Representative immunoblots from four independent experiments. 1, control; 2, CCL2 (100 ng/mL, 24 h); 3, CCL2 (100 ng/mL) + C1142 (30 Ag/mL); 4, CCL2 (100 ng/mL) + CNTO888 (30 Ag/mL); 5, C1142 (30 Ag/mL); 6, CNTO888 (30 Ag/Ml).

Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., ... & Pienta, K. J. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer research, 67(19), 9417-9424.

Figure 2 In vivo bioluminescent imaging of PC-3Luc cell metastasis during systemic CCL2-targeted therapy.

Figure 2 In vivo bioluminescent imaging of PC-3Luc cell metastasis during systemic CCL2-targeted therapy.

D to G, representative pictures illustrate images captured on day 35 from representative animals from each group: D, huIgG; E, CNTO888; F, C1322; and G, C1142.

Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., ... & Pienta, K. J. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer research, 67(19), 9417-9424.

Figure 3 Anti-CCL2 antibodies in combination with docetaxel induce tumor regression in vivo.

Figure 3 Anti-CCL2 antibodies in combination with docetaxel induce tumor regression in vivo.

inhibition of CCL2 in combination with docetaxel (MTD 40mg/kg) was assessed by bioluminescent imaging and quantification of total tumor burden and compared with docetaxel alone. Mice received PC-3Luc cells by intracardiac injection. Beginning on day 14, mice received PBS ( ), docetaxel + CNTO888 (.), docetaxel + C1142 (5), docetaxel + CNTO888 + C1142 ( ), or docetaxel ( w ) by i.p. injection. Docetaxel was administered every week for 3 wks (weeks 2–4), whereas antibodies were delivered twice per week for 6 wks (weeks 2–8). On week 8, all antibody treatments were stopped and tumor progression was monitored to week 12. [arrow (1), initiation of treatment; arrow (2), cessation of docetaxel; arrow (3), cessation of antibody therapy]. Statistical significance was determined at week 10between the docetaxel group and the combination docetaxel + antibody groups.
Overall significance by ANOVA revealed a significant difference between docetaxel only and docetaxel + antibody groups (P < 0.0001). Individual t tests revealed significant differences between docetaxel only and docetaxel + CNTO888 (P = 0.0003), docetaxel + C1142 (P = 0.0001), or docetaxel + C1142 + CNTO888 (P = 0.0001). Solid lines, human antibodies; dashed lines, mouse antibodies.

Loberg, R. D., Ying, C., Craig, M., Day, L. L., Sargent, E., Neeley, C., ... & Pienta, K. J. (2007). Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer research, 67(19), 9417-9424.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG
  • Specificity
  • Tested positive against native Human MCP1
  • Species Reactivity
  • Human
  • Clone
  • cnto888
  • Applications
  • WB 1:1000-1:5000
    ELISA 1:10000-1:20000
    FuncS (assay dependent)

Product Property

  • Purity
  • >95% by SDS-PAGE and HPLC analysis
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Applications

  • Application Notes
  • Assay-depended

Target

  • Alternative Names
  • CCL2; chemokine (C-C motif) ligand 2; HC11; MCAF; MCP1; MCP-1; SCYA2; GDCF-2; SMC-CF; HSMCR30; C-C motif chemokine 2; small-inducible cytokine A2; monocyte secretory protein JE; monocyte chemotactic protein 1; monocyte chemoattractant protein 1; monocyte chemoattractant protein-1; monocyte chemotactic and activating factor; small inducible cytokine subfamily A (Cys-Cys), member 2; small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je)

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone cnto888"

See other products for "CCL2"

Single-domain Antibody

CAT Product Name Application Type
NABG-038 Recombinant Anti-Human CCL2 VHH Single Domain Antibody WB, ELISA, IHC, FuncS Llama VHH

Human Antibody

Fab Fragment Antibody

scFv Fragment Antibody

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-117 Afuco™ Anti-CCL2 ADCC Recombinant Antibody (Carlumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABX-141. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare